SHL:XETRA-Siemens Healthineers AG (EUR)

COMMON STOCK | Medical Devices | XETRA

Last Closing Price

EUR 51.66

Change

-0.58 (-1.11)%

Market Cap

EUR 58.52B

Volume

0.55M

Avg Analyst Target

EUR 69.65 (+34.82%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


SHL Stock Forecast & Price:
Based on the Siemens Healthineers AG stock forecasts from 6 analysts, the average analyst target price for Siemens Healthineers AG is EUR 69.65 over the next 12 months. Siemens Healthineers AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Siemens Healthineers AG is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Siemens Healthineers AG’s stock price was EUR 51.66. Siemens Healthineers AG’s stock price has changed by +0.90% over the past week, +7.67% over the past month and -12.74% over the last year.

About Siemens Healthineers AG (SHL:XETRA)

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. Th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABL:XETRA Abbott Laboratories

-0.20 (-0.18%)

EUR192.05B 23.09 14.09
2M6:XETRA Medtronic PLC

+0.48 (+0.53%)

EUR121.88B 24.99 15.32
SYK:XETRA Stryker Corporation

+1.50 (+0.70%)

EUR79.84B 39.60 25.67
PHI1:XETRA Koninklijke Philips NV

-0.17 (-0.88%)

EUR17.53B 44.80 13.53
SBS:XETRA STRATEC Biomedical AG

-0.40 (-0.43%)

EUR1.12B 28.49 17.40
EUZ:XETRA Eckert & Ziegler Strahlen- und..

+1.36 (+2.99%)

EUR0.92B 34.28 18.76
DRW8:XETRA Drägerwerk AG & Co. KGaA

-0.05 (-0.11%)

EUR0.89B 23.82 -20.62
DRW3:XETRA Draegerwerk VZO O.N.

+0.20 (+0.40%)

EUR0.86B 26.56 -20.62
GME:XETRA Geratherm Medical AG

N/A

EUR0.04B 359.00 18.91
AAQ1:XETRA aap Implantate AG

N/A

EUR0.01B N/A -33.35

ETFs Containing SHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.51% 50% F 15% F
Dividend Return 1.29% 78% C+ 38% F
Total Return -20.22% 50% F 15% F
Trailing 12 Months  
Capital Gain -13.12% 83% B 28% F
Dividend Return 1.43% 67% D+ 32% F
Total Return -11.69% 83% B 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 13.34% 85% B 76% C
Dividend Return 0.82% 45% F 47% F
Total Return 14.16% 85% B 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 19.37% 69% D+ 41% F
Risk Adjusted Return 73.08% 85% B 80% B-
Market Capitalization 58.52B 75% C 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.29 50% F 26% F
Price/Book Ratio 3.10 45% F 33% F
Price / Cash Flow Ratio 19.95 36% F 18% F
EV/EBITDA 14.25 50% F 25% F
Management Effectiveness  
Return on Equity 12.09% 64% D 54% F
Return on Invested Capital 13.09% 58% F 72% C-
Return on Assets 4.23% 58% F 60% D-
Debt to Equity Ratio 0.12% 100% A+ 96% A
Technical Ratios  
Dividend Yield 1.67% 60% D- 41% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.57 50% F 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.